New drug tested for patients with Treatment-Resistant transplant complication
Disease control
Recruiting now
This early-stage study is testing a new drug called Q702 in patients with chronic graft-versus-host disease that hasn't improved with standard treatments. The main goal is to check if the drug is safe and determine the right dose for future studies. Researchers will enroll 18 pat…
Phase: PHASE1 • Sponsor: Qurient Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC